


WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Thursday, August 26, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L15	L14 AND calcium	1471
<input type="checkbox"/>	L14	GPCR	2183
<input type="checkbox"/>	L13	L12 AND calcium	459
<input type="checkbox"/>	L12	L11 AND GPCR	483
<input type="checkbox"/>	L11	536/23.5.CCLS.	8564
<input type="checkbox"/>	L10	L9 AND calcium	577
<input type="checkbox"/>	L9	L8 AND GPCR	615
<input type="checkbox"/>	L8	530/350.CCLS.	15141
<input type="checkbox"/>	L7	L6 AND calcium	627
<input type="checkbox"/>	L6	L5 AND GPCR	663
<input type="checkbox"/>	L5	435/325.CCLS.	15613
<input type="checkbox"/>	L4	Lin.IN.	44231
<input type="checkbox"/>	L3	Lin-D.IN.	402
<input type="checkbox"/>	L2	Lin-Dan.IN.	0
<input type="checkbox"/>	L1	(Lin-Daniel.IN.)	25

END OF SEARCH HISTORY



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
 Search PubMed for GPCR AND calcium AND citric acid Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 20 Sort Send to Text
 Items 1-6 of 6 One page.

☐ 1: Ricciardolo FL.

Related Articles, Links

Mechanisms of citric acid-induced bronchoconstriction.

Am J Med. 2001 Dec 3;111 Suppl 8A:18S-24S. Review.

PMID: 11749919 [PubMed - indexed for MEDLINE]

☐ 2: Zhang Y, Chou JH, Bradley J, Bargmann CI, Zinn K.

Related Articles, Links

The Caenorhabditis elegans seven-transmembrane protein ODR-10 functions as an odorant receptor in mammalian cells.

Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12162-7.

PMID: 9342380 [PubMed - indexed for MEDLINE]

☐ 3: Nederfors T, Dahlof C.

Related Articles, Links

Effects on salivary flow rate and composition of withdrawal of and re-exposure to the beta 1-selective antagonist metoprolol in a hypertensive patient population.

Eur J Oral Sci. 1996 Jun;104(3):262-8.

PMID: 8831060 [PubMed - indexed for MEDLINE]

☐ 4: Jensen JL, Xu T, Lamkin MS, Brodin P, Aars H, Berg T, Oppenheim FG.

Related Articles, Links

Physiological regulation of the secretion of histatins and statherins in human parotid saliva.

J Dent Res. 1994 Dec;73(12):1811-7.

PMID: 7814752 [PubMed - indexed for MEDLINE]

☐ 5: Bretschneider E, Glusa E, Schror K.

Related Articles, Links

ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca⁺⁺ concentrations.

Thromb Res. 1994 Aug 1;75(3):233-42.

PMID: 7992234 [PubMed - indexed for MEDLINE]

☐ 6: Hammerschmidt DE, Jeanneret C, Husak M, Lobell M, Jacob HS.

Related Articles, Links

Lymphocyte aggregation in response to adrenergic stimulation.

Blood. 1988 May;71(5):1470-4.

PMID: 2896030 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text


Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for Carninci AND Normalization Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 20 Sort Send to Text
 Items 1-3 of 3 One page.

☐ 1: [Hirozane-Kishikawa T, Shiraki T, Waki K, Nakamura M, Arakawa T, Kawai J, Fagiolini M, Hensch TK, Hayashizaki Y, Carninci P.](#) Related Articles, Links

Subtraction of cap-trapped full-length cDNA libraries to select rare transcripts.

Biotechniques. 2003 Sep;35(3):510-6, 518.

PMID: 14513556 [PubMed - indexed for MEDLINE]

☐ 2: [Carninci P, Waki K, Shiraki T, Konno H, Shibata K, Itoh M, Aizawa K, Arakawa T, Ishii Y, Sasaki D, Bono H, Kondo S, Sugahara Y, Saito R, Osato N, Fukuda S, Sato K, Watabiki A, Hirozane-](#) Related Articles, Links

[Kishikawa T, Nakamura M, Shibata Y, Yasunishi A, Kikuchi N,](#)

[Yoshiki A, Kusakabe M, Gustincich S, Beisel K, Pavan W, Aidinis](#)

[V, Nakagawara A, Held WA, Iwata H, Kono T, Nakauchi H, Lyons](#)

[P, Wells C, Hume DA, Fagiolini M, Hensch TK, Brinkmeier M,](#)

[Camper S, Hirota J, Mombaerts P, Muramatsu M, Okazaki Y, Kawai](#)

[J, Hayashizaki Y.](#)

Targeting a complex transcriptome: the construction of the mouse full-length cDNA encyclopedia.

Genome Res. 2003 Jun;13(6B):1273-89.

PMID: 12819125 [PubMed - indexed for MEDLINE]

☐ 3: [Carninci P, Shibata Y, Hayatsu N, Sugahara Y, Shibata K, Itoh M, Konno H, Okazaki Y, Muramatsu M, Hayashizaki Y.](#) Related Articles, Links

Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes.

Genome Res. 2000 Oct;10(10):1617-30.

PMID: 11042159 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for Itoh AND 2000 AND Konno

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 20 Sort Send to Text

Items 1-6 of 6 One page.

- ☐ 1: [Shibata K, Itoh M, Aizawa K, Nagaoka S, Sasaki N, Carninci P, Konno H, Akiyama I, Nishi K, Kitsuai T, Tashiro H, Itoh M, Sumi N, Ishii Y, Nakamura S, Hazama M, Nishine T, Harada A, Yamamoto R, Matsumoto H, Sakaguchi S, Ikegami T, Kashiwagi K, Fujiwaka S, Inoue K, Togawa Y.](#) Related Articles, Links

RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer.
Genome Res. 2000 Nov;10(11):1757-71.
PMID: 11076861 [PubMed - indexed for MEDLINE]

- ☐ 2: [Carninci P, Shibata Y, Hayatsu N, Sugahara Y, Shibata K, Itoh M, Konno H, Okazaki Y, Muramatsu M, Hayashizaki Y.](#) Related Articles, Links

Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes.
Genome Res. 2000 Oct;10(10):1617-30.
PMID: 11042159 [PubMed - indexed for MEDLINE]

- ☐ 3: [Tomita F, Kohya T, Sakurai M, Kaji T, Yokoshiki H, Sato M, Sasaki K, Itoh Y, Konno M, Kitabatake A, Hokkaido Atrial Fibrillation Study Group.](#) Related Articles, Links

Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan.
Jpn Circ J. 2000 Sep;64(9):653-8.
PMID: 10981848 [PubMed - indexed for MEDLINE]

- ☐ 4: [Adachi I, Morita K, Imran MB, Konno M, Mochizuki T, Kubo N, Itoh Y, Kato C, Tsukamoto E, Tamaki N.](#) Related Articles, Links

Heterogeneity of myocardial wall motion and thickening in the left ventricle evaluated with quantitative gated SPECT.
J Nucl Cardiol. 2000 Jul-Aug;7(4):296-300.
PMID: 10958270 [PubMed - indexed for MEDLINE]

- ☐ 5: [Itoh S, Yanagishita T, Aoki S, Koba S, Iwata T, Ishioka H, Arata H, Mukae S, Geshi E, Konno N, Katagiri T, Utsumi H.](#) Related Articles, Links


Generation of free radicals and the damage done to the sarcoplasmic reticulum during reperfusion injury following brief ischemia in the canine heart.
Jpn Circ J. 1999 May;63(5):373-8.
PMID: 10943617 [PubMed - indexed for MEDLINE]

- ☐ 6: [Sato M, Ishida H, Konno K, Komatsuda T, Naganuma H, Watanabe S, Ohyama Y, Itoh M, Mukojima T, Sakai T.](#) Related Articles, Links

Mesenteric panniculitis: sonographic findings.
Abdom Imaging. 2000 Mar-Apr;25(2):142-5.
PMID: 10675455 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

[Write to the Help Desk](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search **PubMed** for

Limits Preview/Index History Clipboard Details

About Entrez

Abstract Show: Sort **Text**

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Genome Res. 2000 Nov;10(11):1757-71.

Related Articles, Links

FREE full text article at
www.genome.org

RIKEN integrated sequence analysis (RISA) system—384-format sequencing pipeline with 384 multicapillary sequencer.

Shibata K, Itoh M, Aizawa K, Nagaoka S, Sasaki N, Carninci P, Konno H, Akiyama J, Nishi K, Kitsunai T, Tashiro H, Itoh M, Sumi N, Ishii Y, Nakamura S, Hazama M, Nishine T, Harada A, Yamamoto R, Matsumoto H, Sakaguchi S, Ikegami T, Kashiwagi K, Fujiwake S, Inoue K, Togawa Y.

Genome Exploration Research Group, RIKEN, Genomic Sciences Center (GSC) and Genome Science Laboratory, RIKEN, Tsukuba Institute, Core Research of Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Ibaraki, Japan.

The RIKEN high-throughput 384-format sequencing pipeline (RISA system) including a 384-multicapillary sequencer (the so-called RISA sequencer) was developed for the RIKEN mouse encyclopedia project. The RISA system consists of colony picking, template preparation, sequencing reaction, and the sequencing process. A novel high-throughput 384-format capillary sequencer system (RISA sequencer system) was developed for the sequencing process. This system consists of a 384-multicapillary auto sequencer (RISA sequencer), a 384-multicapillary array assembler (CAS), and a 384-multicapillary casting device. The RISA sequencer can simultaneously analyze 384 independent sequencing products. The optical system is a scanning system chosen after careful comparison with an image detection system for the simultaneous detection of the 384-capillary array. This scanning system can be used with any fluorescent-labeled sequencing reaction (chain termination reaction), including transcriptional sequencing based on RNA polymerase, which was originally developed by us, and cycle sequencing based on thermostable DNA polymerase. For long-read sequencing, 380 out of 384 sequences (99.2%) were successfully analyzed and the average read length, with more than 99% accuracy, was 654.4 bp. A single RISA sequencer can analyze 216 kb with >99% accuracy in 2.7 h (90 kb/h). For short-read sequencing to cluster the 3' end and 5' end sequencing by reading 350 bp, 384 samples can be analyzed in 1.5 h. We have also developed a RISA inoculator, RISA filtrator and densitometer, RISA plasmid preparator which can handle throughput of 40,000 samples in 17.5 h, and a high-throughput RISA thermal cycler which has four 384-well sites. The combination of these technologies allowed us to construct the RISA system consisting of 16 RISA sequencers, which can process 50,000 DNA samples per day. One haploid genome shotgun sequence of a higher organism, such as

human, mouse, rat, domestic animals, and plants, can be revealed by seven RISA systems within one month.

PMID: 11076861 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for [] Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Genome Res. 2000 Oct;10(10):1617-30.

Related Articles, Links

Comment in:

- Genome Res. 2000 Oct;10(10):1431-2.

FREE full text article at
www.genome.org

Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes.

Carninci P, Shibata Y, Hayatsu N, Sugahara Y, Shibata K, Itoh M, Konno H, Okazaki Y, Muramatsu M, Hayashizaki Y.

Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center, Tsukuba, Japan. rgscerg@rtc.riken.go.jp

In the effort to prepare the mouse full-length cDNA encyclopedia, we previously developed several techniques to prepare and select full-length cDNAs. To increase the number of different cDNAs, we introduce here a strategy to prepare normalized and subtracted cDNA libraries in a single step. The method is based on hybridization of the first-strand, full-length cDNA with several RNA drivers, including starting mRNA as the normalizing driver and run-off transcripts from minilibraries containing highly expressed genes, rearranged clones, and previously sequenced cDNAs as subtracting drivers. Our method keeps the proportion of full-length cDNAs in the subtracted/normalized library high. Moreover, our method dramatically enhances the discovery of new genes as compared to results obtained by using standard, full-length cDNA libraries. This procedure can be extended to the preparation of full-length cDNA encyclopedias from other organisms.

PMID: 11042159 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

Connecting via Winsock to STN
Welcome to STN International! Enter x:x
***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:11:00 ON 26 AUG 2004

=> file BIOSCIENCE

FILE 'ADISCTI' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'AQUALINE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'CAPLUS' ENTERED AT 12:11:10 ON 26 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:11:10 ON 26 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:11:10 ON 26 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'FOMAD' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'HEALSAFE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:11:10 ON 26 AUG 2004

FILE 'NIOSHTIC' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:11:10 ON 26 AUG 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 12:11:10 ON 26 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:11:10 ON 26 AUG 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:11:10 ON 26 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 12:11:10 ON 26 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:11:10 ON 26 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 12:11:10 ON 26 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S GPCR OR g-protein-coupled-receptor

6 FILES SEARCHED...

14 FILES SEARCHED...

25 FILES SEARCHED...

33 FILES SEARCHED...

49 FILES SEARCHED...

63 FILES SEARCHED...

L1 157620 GPCR OR G-PROTEIN-COUPLED-RECEPTOR

=> S L1 AND calcium

36 FILES SEARCHED...

L2 16298 L1 AND CALCIUM

=> S L2 AND citric acid

24 FILES SEARCHED...

25 FILES SEARCHED...

41 FILES SEARCHED...

63 FILES SEARCHED...

L3 1057 L2 AND CITRIC ACID

=> DUP REM L3

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY 79% COMPLETE FOR L3
PROCESSING COMPLETED FOR L3

L4 968 DUP REM L3 (89 DUPLICATES REMOVED)

=> S L4 AND PY<=2000

'2000' NOT A VALID FIELD CODE

6 FILES SEARCHED...

8 FILES SEARCHED...

12 FILES SEARCHED...

15 FILES SEARCHED...

20 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

29 FILES SEARCHED...

33 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

43 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

47 FILES SEARCHED...

52 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

58 FILES SEARCHED...

'2000' NOT A VALID FIELD CODE

63 FILES SEARCHED...

67 FILES SEARCHED...

69 FILES SEARCHED...

L5 66 L4 AND PY<=2000

=> D L5 1-66

L5 ANSWER 1 OF 66 USPATFULL on STN

AN 2004:205782 USPATFULL

TI Receptor protein and method for diagnosing inflammatory diseases by using the same

IN Takahashi, Tsuneo, Tokyo, JAPAN

Ono, Mitsuharu, Shizuoka-Ken, JAPAN

Ishimaru, Hiroshi, Kanagawa-Ken, JAPAN

Kanno, Kimiyoshi, Shizuoka-Ken, JAPAN

Takahashi, Chiaki, Shizuoka-Ken, JAPAN

PA Asahi Kasei Kabushiki Kaisha, Osaka, JAPAN (non-U.S. corporation)

PI US 6777204 B1 20040817

WO 2000014229 20000316

AI US 2001-786442 20010305 (9) <--

WO 1999-JP4801 19990903

PRAI JP 1998-249752 19980903

JP 1999-70800 19990316

DT Utility

FS GRANTED

LN.CNT 3082

INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.500;
530/300.000; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.500;
530/300.000; 530/350.000
IC [7]
ICM: C12P021-06
ICS: C07K001-00; A61K038-00; C12N015-74; C07H021-04
EXF 530/350; 530/300; 435/69.1; 435/252.3; 435/320.1; 435/325; 435/471;
435/761; 435/71.1; 435/71.2; 435/771; 536/23.5

L5 ANSWER 2 OF 66 USPATFULL on STN
AN 2004:79027 USPATFULL
TI .beta.2-adrenergic receptor agonists
IN Moran, Edmund J., San Francisco, CA, United States
Choi, Seok-Ki, Palo Alto, CA, United States
PA Theravance, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6713651 B1 20040330
WO 9964035 19991216
AI US 2000-674451 20001101 (9) <--
WO 1999-US11804 19990607
DT Utility
FS GRANTED
LN.CNT 3616
INCL INCLM: 564/372.000
INCLS: 548/326.000; 548/346.000; 548/440.000; 548/486.000; 548/490.000;
549/404.000; 424/001.110; 424/009.100; 424/178.100; 424/198.100;
435/007.100; 435/007.200; 436/501.000; 436/518.000; 564/347.000;
564/503.000; 544/062.000; 544/360.000; 544/363.000; 544/370.000;
544/372.000; 544/373.000; 544/380.000; 544/382.000; 546/156.000
NCL NCLM: 564/372.000
NCLS: 424/009.100; 424/178.100; 424/198.100; 435/007.100; 435/007.200;
436/501.000; 436/518.000; 514/255.030; 544/062.000; 544/360.000;
544/363.000; 544/370.000; 544/372.000; 544/373.000; 544/380.000;
544/382.000; 546/156.000; 548/326.100; 548/346.100; 548/440.000;
548/486.000; 548/490.000; 549/404.000; 564/347.000; 564/503.000
IC [7]
ICM: C07C211-00
ICS: C07C213-00; C07D401-00; C07D215-16; C07D209-82
EXF 424/1.11; 424/9.1; 424/178.1; 424/193.1; 435/7.1; 435/7.2; 436/501;
436/518; 564/372; 564/347; 564/503; 544/62; 544/360; 544/363; 544/370;
544/372; 544/373; 544/380; 544/382; 546/156; 548/326; 548/346; 548/440;
548/486; 548/490; 549/404

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 66 USPATFULL on STN
AN 2004:53402 USPATFULL
TI Peptides that activate the ***G*** - ***protein*** ***coupled***
receptor protein, OT7T175
IN Watanabe, Takuya, Osaka, JAPAN
Terao, Yasuko, Ibaraki, JAPAN
Shintani, Yasushi, Ibaraki, JAPAN
Ohtaki, Tetsuya, Ibaraki, JAPAN
Kanehashi, Kimiko, Ibaraki, JAPAN
Kitada, Chieko, Osaka, JAPAN
PA Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6699965 B1 20040302
WO 2000024890 20000504
AI US 2001-830428 20010426 (9)
WO 1999-JP5905 19991026
PRAI JP 1998-305949 19981027
JP 1999-27710 19990204
JP 1999-57207 19990304
JP 1999-276225 19990929
DT Utility
FS GRANTED
LN.CNT 3649
INCL INCLM: 530/300.000
INCLS: 530/326.000; 530/327.000; 530/328.000; 514/002.000; 514/014.000;
514/015.000; 514/016.000
NCL NCLM: 530/300.000
NCLS: 530/326.000; 530/327.000; 530/328.000
IC [7]
ICM: C07K014-00

ICS: C07K007-00; A61K038-00; A61K038-04
EXF 530/300; 530/327; 530/328; 530/326; 530/350; 514/2; 514/14; 514/15;
514/16; 424/85.1; 424/184.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 66 USPATFULL on STN
AN 2002:317435 USPATFULL
TI C3A receptor ligands
IN Lee, Dennis, San Mateo, CA, United States
Bondinell, William E., Wayne, PA, United States
Jurewicz, Anthony J., Royersford, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.
corporation)
PI US 6489339 B1 20021203
WO 2000009129 20000224
AI US 2001-762459 20010207 (9) <--
WO 1999-US18256 19990811
PRAI US 1998-96055P 19980811 (60)
DT Utility
FS GRANTED
LN.CNT 761
INCL INCLM: 514/311.000
INCLS: 514/563.000; 546/175.000; 562/439.000
NCL NCLM: 514/311.000
NCLS: 514/563.000; 546/175.000; 562/439.000
IC [7]
ICM: A61K031-47
ICS: A61K031-198; A61P019-02; C07D215-20
EXF 546/175; 562/439; 514/311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 66 USPATFULL on STN
AN 2002:268750 USPATFULL
TI Azepine derivatives having effects on serotonin related systems
IN Hauser, Kenneth Lee, Greencastle, IN, United States
Hertel, Larry Wayne, Indianapolis, IN, United States
Xu, Yao-Chang, Fishers, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 6465453 B1 20021015
WO 2000000203 20000106 <--
AI US 2000-701363 20001128 (9)
WO 1999-US14778 19990629
PRAI US 1998-91245P 19980630 (60) PCT 371 date
DT Utility
FS GRANTED
LN.CNT 2882
INCL INCLM: 514/217.030
INCLS: 514/217.080; 540/596.000; 540/602.000
NCL NCLM: 514/217.030
NCLS: 514/217.080; 540/596.000; 540/602.000
IC [7]
ICM: A61K031-55
ICS: A61P025-24; C07D403-00; C07D405-00; C07D409-00
EXF 514/217.03; 514/217.08; 540/596; 540/602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 66 USPATFULL on STN
AN 2002:262381 USPATFULL
TI Substituted .alpha., .beta.-anellated butyrolactones
IN stolle, Andreas, Milford, CT, United States
Antonicek, Horst-Peter, Gladbach, GERMANY, FEDERAL REPUBLIC OF
Lensky, Stephen, Kurten, GERMANY, FEDERAL REPUBLIC OF
Voerste, Arnd, Koln, GERMANY, FEDERAL REPUBLIC OF
Muller, Thomas, Bonn, GERMANY, FEDERAL REPUBLIC OF
Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
von dem Bruch, Karsten, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Muller, Gerhard, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Stropp, Udo, Haan, GERMANY, FEDERAL REPUBLIC OF
Horvath, Ervin, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
de Vry, Jean-Marie-Viktor, Rosrath, GERMANY, FEDERAL REPUBLIC OF
Schreiber, Rudy, Koln, GERMANY, FEDERAL REPUBLIC OF
PA Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
(non-U.S. corporation)
PI US 6462074 B1 20021008

WO 9936416 19990722
AI US 2000-600355 20000714 (9) <--
WO 1999-EP9800132 19990112
20000714 PCT 371 date
PRAI DE 1998-19801646 19980117
DT Utility
FS GRANTED
LN.CNT 2242
INCL INCLM: 514/432.000
INCLS: 514/438.000; 514/470.000; 549/060.000; 549/305.000; 549/311.000;
549/367.000; 549/432.000; 549/438.000
NCL NCLM: 514/432.000
NCLS: 514/438.000; 514/470.000; 549/060.000; 549/305.000; 549/311.000;
549/367.000; 549/432.000; 549/438.000
IC [7]
ICM: A61K031-343
ICS: A61K031-381; C07D307-93; C07D317-14; C07D323-00
EXF 514/470; 514/432; 514/438; 549/304; 549/60; 549/305; 549/311; 549/367;
549/431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 66 USPATFULL on STN
AN 2002:209547 USPATFULL
TI Piperidine derivatives having effects on serotonin related systems
IN Hertel, Larry Wayne, Indianapolis, IN, United States
Kohlman, Daniel Timothy, Camby, IN, United States
Liang, Sidney Xi, Fishers, IN, United States
Wong, David Taiwai, Indianapolis, IN, United States
Xu, Yao-Chang, Fishers, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 6436964 B1 20020820
WO 2000000198 20000106
AI US 2000-701406 20001128 (9) <--
WO 1999-US14732 19990629
20001128 PCT 371 date
PRAI US 1998-91241P 19980630 (60)
DT Utility
FS GRANTED
LN.CNT 3433
INCL INCLM: 514/333.000
INCLS: 546/256.000
NCL NCLM: 514/333.000
NCLS: 546/256.000
IC [7]
ICM: C07D405-06
ICS: A61K031-444
EXF 546/256; 514/333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 66 USPATFULL on STN
AN 2002:202120 USPATFULL
TI Substituted .beta.,.gamma.-anellated lactones
IN Stolle, Andreas, Milford, CT, United States
Antonicek, Horst-Peter, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF
Lensky, Stephen, Kurten, GERMANY, FEDERAL REPUBLIC OF
Voerste, Arnd, Koln, GERMANY, FEDERAL REPUBLIC OF
Müller, Thomas, Bonn-Beuel, GERMANY, FEDERAL REPUBLIC OF
Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
von dem Bruch, Karsten, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Müller, Gerhard, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Stropp, Udo, Haan, GERMANY, FEDERAL REPUBLIC OF
Horvath, Ervin, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
de Vry, Jean-Marie-Viktor, Rosrath, GERMANY, FEDERAL REPUBLIC OF
Schreiber, Rudy, Koln, GERMANY, FEDERAL REPUBLIC OF
PA Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
(non-U.S. corporation)
PI US 6433004 B1 20020813
WO 9936417 19990722
AI US 2000-600430 20000714 (9) <--
WO 1999-EP22 19990105
20000714 PCT 371 date
PRAI DE 1998-19801647 19980117
DT Utility
FS GRANTED
LN.CNT 686

INCL INCLM: 514/443.000
INCLS: 514/444.000; 514/468.000; 514/470.000; 549/058.000; 549/301.000;
549/307.000; 549/312.000
NCL NCLM: 514/443.000
NCLS: 514/444.000; 514/468.000; 514/470.000; 549/058.000; 549/301.000;
549/307.000; 549/312.000
IC [7]
ICM: A61K031-381
ICS: C07D307-83; C07D307-935; C07D333-56; C07D407-04
EXF 514/443; 514/444; 514/468; 514/470; 549/58; 549/301; 549/307; 549/312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 66 USPATFULL on STN
AN 2002:88520 USPATFULL
TI Substituted bicyclic lactones
IN Stolle, Andreas, Milford, CT, United States
Antonicek, Horst-Peter, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF
Lensky, Stephen, Kurten, GERMANY, FEDERAL REPUBLIC OF
Voerste, Arnd, Koln, GERMANY, FEDERAL REPUBLIC OF
Muller, Thomas, Bonn-Beuel, GERMANY, FEDERAL REPUBLIC OF
Baumgarten, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
von dem Bruch, Karsten, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Muller, Gerhard, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Stropp, Udo, Haan, GERMANY, FEDERAL REPUBLIC OF
Horvath, Ervin, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
de Vry, Jean-Marie-Viktor, Rosrath, GERMANY, FEDERAL REPUBLIC OF
Schreiber, Rudy, Koln, GERMANY, FEDERAL REPUBLIC OF
PA Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
(non-U.S. corporation)
PI US 6376539 B1 20020423
WO 9936418 19990722
AI US 2000-600395 20000714 (9) <--
WO 1999-EP31 19990107
20000714 PCT 371 date
PRAI DE 1998-19801636 19980117
DT Utility
FS GRANTED
LN.CNT 2022
INCL INCLM: 514/470.000
INCLS: 514/444.000; 514/462.000; 549/060.000; 549/229.000; 549/295.000;
549/297.000; 549/302.000; 549/304.000; 549/305.000
NCL NCLM: 514/470.000
NCLS: 514/444.000; 514/462.000; 549/060.000; 549/229.000; 549/295.000;
549/297.000; 549/302.000; 549/304.000; 549/305.000
IC [7]
ICM: A61K031-34
ICS: A61K031-335
EXF 549/295; 549/60; 549/229; 549/302; 549/304; 549/305; 549/297; 514/444;
514/462; 514/470
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 66 USPATFULL on STN
AN 2002:45628 USPATFULL
TI Pyrrolidine and pyrroline derivatives having effects on serotonin
related systems
IN Hertel, Larry Wayne, Indianapolis, IN, United States
Xu, Yao-Chang, Fishers, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 6353008 B1 20020305
WO 2000000196 20000106 <--
AI US 2000-701361 20001128 (9)
WO 1999-US14881 19990629
20001128 PCT 371 date
PRAI US 1998-91204P 19980630 (60)
DT Utility
FS GRANTED
LN.CNT 2949
INCL INCLM: 514/343.000
INCLS: 514/414.000; 514/422.000; 546/276.400; 548/525.000; 548/466.000
NCL NCLM: 514/343.000
NCLS: 514/414.000; 514/422.000; 546/276.400; 548/466.000; 548/525.000
IC [7]
ICM: A61K031-44
ICS: C07D405-02
EXF 546/276.4; 548/525; 548/466; 514/343; 514/422; 514/414

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 66 USPATFULL on STN
AN 2001:67795 USPATFULL
TI Polypeptides their production and use
IN Hinuma, Shuji, Tsukuba, Japan
Habata, Yugo, Tsukuba, Japan
Kawamata, Yuji, Tsukuba, Japan
Hosoya, Masaki, Tsuchiura, Japan
Fujii, Ryo, Tsukuba, Japan
Fukusumi, Shoji, Tsukuba, Japan
Kitada, Chieko, Sakai, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 6228984 B1 20010508
WO 9724436 19970710
AI US 1997-776971 19970207 (8) <--
WO 1996-JP3821 19961228
19970206 PCT 371 date
19970206 PCT 102(e) date
PRAI JP 1995-343371 19951228
JP 1996-59419 19960315
JP 1996-211805 19960812
JP 1996-246573 19960918
DT Utility
FS Granted
LN.CNT 4756
INCL INCLM: 530/300.000
INCLS: 424/198.100; 435/069.400; 435/252.300; 514/012.000; 536/023.510
NCL NCLM: 530/300.000
NCLS: 424/198.100; 435/069.400; 435/252.300; 536/023.510
IC [7]
ICM: C07K014-47
ICS: C12N015-12; A61K038-17
EXF 424/198.1; 435/252.3; 435/69.4; 514/12; 530/300; 536/23.51
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 66 USPATFULL on STN
AN 2001:40474 USPATFULL
TI Non-peptidyl vasopressin V1a antagonists
IN Bruns, Jr., Robert F, Carmel, IN, United States
Cooper, Robin DG, Indianapolis, IN, United States
Dressman, Bruce A, Indianapolis, IN, United States
Hunden, David C, Carmel, IN, United States
Kaldor, Stephen W, Indianapolis, IN, United States
Koppel, Gary A, Indianapolis, IN, United States
Rizzo, John R, Indianapolis, IN, United States
Skelton, Jeffrey J, Indianapolis, IN, United States
Steinberg, Mitchell I, Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6204260 B1 20010320
WO 9730707 19970828
AI US 1999-125737 19990819 (9) <--
WO 1997-US3039 19970220
19990819 PCT 371 date
19990819 PCT 102(e) date
PRAI GB 1996-5044 19960309
GB 1996-5045 19960309
GB 1996-5046 19960309
US 1996-12149P 19960223 (60)
US 1996-12188P 19960223 (60)
US 1996-12215P 19960223 (60)
DT Utility
FS Granted
LN.CNT 3548
INCL INCLM: 514/210.100
INCLS: 540/200.000
NCL NCLM: 514/210.100
NCLS: 540/200.000
IC [7]
ICM: A61K031-395
ICS: C07D205-00
EXF 540/200; 514/210
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 66 USPATFULL on STN

AN 2000:164488 USPATFULL
TI Azole peptidomimetics as thrombin receptor antagonists
IN Hoekstra, William, Villanova, PA, United States
PA Ortho-McNeil Pharmaceuticals, Inc., Raritan, NJ, United States (U.S. corporation)
PI US 6156732 20001205
AI US 1999-387489 19990901 (9) <--
RLI Division of Ser. No. US 1999-245739, filed on 8 Feb 1999, now patented, Pat. No. US 6017890
DT Utility
FS Granted
LN.CNT 696
INCL INCLM: 514/018.000
INCLS: 514/002.000; 514/017.000; 514/822.000
NCL NCLM: 514/018.000
NCLS: 514/002.000; 514/017.000; 514/822.000
IC [7]
ICM: A61K038-03
ICS: A61K038-04; A61K038-07; A61K038-08
EXF 514/2; 514/17; 514/18; 514/822
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 66 USPATFULL on STN
AN 2000:150170 USPATFULL
TI Alpha 1a adrenergic receptor antagonists
IN Patane, Michael A., Harleysville, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6143750 20001107
AI US 1998-98780 19980617 (9) <--
PRAI US 1997-50960P 19970618 (60)
DT Utility
FS Granted
LN.CNT 2936
INCL INCLM: 514/258.000
INCLS: 514/258.000; 514/259.000; 514/274.000; 544/278.000; 544/280.000; 544/295.000; 544/296.000; 544/316.000
NCL NCLM: 514/255.050
NCLS: 514/260.100; 514/265.100; 514/266.220; 514/274.000; 544/278.000; 544/280.000; 544/295.000; 544/296.000; 544/316.000
IC [7]
ICM: A61K031-505
ICS: A01N043-54; C07D491-00; C07D403-00; C07D239-02
EXF 544/278; 544/280; 544/318; 544/295; 544/296; 544/316; 514/274; 514/258; 514/259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 66 USPATFULL on STN
AN 2000:138332 USPATFULL
TI Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
IN McKay, Robert, San Diego, CA, United States
Dean, Nicholas, Olivenhain, CA, United States
Monia, Brett P., La Costa, CA, United States
Nero, Pamela S., Oceanside, CA, United States
Gaarde, William A., Carlsbad, CA, United States
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6133246 20001017
AI US 1999-287796 19990407 (9) <--
RLI Continuation-in-part of Ser. No. US 1998-130616, filed on 7 Aug 1998 which is a continuation-in-part of Ser. No. US 1997-910629, filed on 13 Aug 1997, now patented, Pat. No. US 5877309
DT Utility
FS Granted
LN.CNT 4754
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/183.000; 435/194.000; 435/325.000; 435/366.000; 435/375.000; 536/023.100; 536/024.310; 536/024.500
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/183.000; 435/194.000; 435/325.000; 435/366.000; 435/375.000; 536/023.100; 536/024.310; 536/024.500
IC [7]
ICM: A01K048-00
ICS: C12N015-11; C12N015-85; C07H021-04

EXF 435/6; 435/69.1; 435/91.1; 435/440; 435/325; 435/352; 435/353; 435/354;
435/366; 435/371; 435/375; 435/320.1; 435/183; 435/194; 536/23.1;
536/24.3; 536/24.31; 536/24.33; 536/24.5; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 66 USPATFULL on STN
AN 2000:128363 USPATFULL
TI Selective NPY (Y5) antagonists (tricyclics)
IN Marzabadi, Mohammad R., Ridgewood, NJ, United States
Wong, Wai C., Hamden, CT, United States
Noble, Stewart A., Wheeling, IL, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S.
corporation)
PI US 6124331 20000926
AI US 1999-343994 19990630 (9) <--
DT Utility
FS Granted
LN.CNT 2088
INCL INCLM: 514/366.000
INCLS: 514/375.000; 514/393.000; 548/218.000; 548/015.100; 548/302.100
NCL NCLM: 514/366.000
NCLS: 514/375.000; 514/393.000; 546/172.000; 548/151.000; 548/218.000;
548/302.100
IC [7]
ICM: A61K031-425
ICS: A61K031-42; C07D513-22; C07D498-00; C07D487-00
EXF 548/151; 548/302.1; 548/218; 514/375; 514/366; 514/393
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 66 USPATFULL on STN
AN 2000:117520 USPATFULL
TI G-protein coupled receptor protein and a DNA encoding the receptor
IN Hinuma, Shuji, Tsukuba, Japan
Hosoya, Masaki, Tsuchiura, Japan
Fujii, Ryo, Tsukuba, Japan
Ohtaki, Tetsuya, Tsukuba, Japan
Fukusumi, Shoji, Tsukuba, Japan
Ohgi, Kazuhiro, Tsukuba, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 6114139 20000905
WO 9605302 19960222
AI US 1995-513974 19950914 (8)
WO 1995-JP1599 19950810
19950914 PCT 371 date
19950914 PCT 102(e) date
PRAI JP 1994-189272 19940811
JP 1994-189273 19940811
JP 1994-189274 19940811
JP 1994-236356 19940930
JP 1994-236357 19940930
JP 1994-270017 19941102
JP 1994-326611 19941228
JP 1995-7177 19950120
JP 1995-57186 19950316
JP 1995-93989 19950419
DT Utility
FS Granted
LN.CNT 13008
INCL INCLM: 435/069.100
INCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12N015-12
ICS: C12N015-63; C12N005-10; C07K014-705
EXF 536/23.5; 435/69.1; 435/325; 435/320.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 66 USPATFULL on STN
AN 2000:102109 USPATFULL
TI o-fucosyltransferase
IN Wang, Yang, Milbrae, CA, United States
Spellman, Michael W., Belmont, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6100076 20000808 <--

AI US 1997-978741 19971126 (8)
RLI Continuation-in-part of Ser. No. US 1997-792498, filed on 31 Jan 1997,
now abandoned
DT Utility
FS Granted
LN.CNT 3438
INCL INCLM: 435/193.000
NCL NCLM: 435/193.000
IC [7]
ICM: C12N009-10
EXF 435/193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 66 USPATFULL on STN
AN 2000:98448 USPATFULL
TI .alpha..sub.1a adrenergic receptor antagonists
IN Hoffman, Jacob M., Lansdale, PA, United States
Chang, Raymond S. L., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6096763 20000801
AI US 1999-282743 19990331 (9) <--
RLI Division of Ser. No. US 860314
DT Utility
FS Granted
LN.CNT 2722
INCL INCLM: 514/321.000
INCLS: 514/322.000; 546/198.000; 546/199.000
NCL NCLM: 514/321.000
NCLS: 514/322.000; 546/198.000; 546/199.000
IC [7]
ICM: A61K031-445
EXF 514/321; 514/322; 546/198; 546/199
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 66 USPATFULL on STN
AN 2000:84420 USPATFULL
TI Human metabotropic glutamate receptor
IN Stormann, Thomas M., Salt Lake City, UT, United States
Simin, Rachel T., Salt Lake City, UT, United States
Hammerland, Lance G., Bountiful, UT, United States
Fuller, Forrest H., Salt Lake City, UT, United States
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.
corporation)
PI US 6084084 20000704
AI US 1996-604298 19960221 (8) <--
DT Utility
FS Granted
LN.CNT 3237
INCL INCLM: 536/023.500
INCLS: 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 536/023.500
NCLS: 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: C07H021-04
ICS: C12P021-06; C12N005-00; C12N015-00
EXF 536/23.1; 536/23.5; 435/320.1; 435/325; 435/69.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 66 USPATFULL on STN
AN 2000:80768 USPATFULL
TI Alpha 1A adrenergic receptor antagonists
IN Patane, Michael A., Harleysville, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6080760 20000627
AI US 1998-98806 19980617 (9) <--
PRAI US 1997-50137P 19970618 (60)
DT Utility
FS Granted
LN.CNT 1855
INCL INCLM: 514/326.000
INCLS: 514/369.000; 514/376.000; 546/209.000; 548/188.000; 548/230.000
NCL NCLM: 514/326.000
NCLS: 514/369.000; 514/376.000; 546/209.000; 548/188.000; 548/230.000
IC [7]
ICM: A61K031-421

ICS: C07D211-32; C07D263-26
EXF 514/326; 514/369; 514/376; 546/209; 548/188; 548/230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 66 USPATFULL on STN
AN 2000:77191 USPATFULL
TI Human metabotropic glutamate receptor
IN Stormann, Thomas M., Salt Lake City, UT, United States
Simin, Rachel T., Salt Lake City, UT, United States
Hammerland, Lance G., Bountiful, UT, United States
Fuller, Forrest H., Salt Lake City, UT, United States
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.
corporation)
PI US 6077675 20000620 <--
AI US 1997-823110 19970324 (8)
RLI Division of Ser. No. US 1996-604298, filed on 21 Feb 1996
DT Utility
FS Granted
LN.CNT 3286
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/069.100
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/069.100
IC [7]
ICM: G01N033-53
EXF 435/7.1; 435/7.2; 435/6; 426/175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 66 USPATFULL on STN
AN 2000:74303 USPATFULL
TI Alpha 1a adrenergic receptor antagonists
IN Patane, Michael A., Harleysville, PA, United States
Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6075038 20000613 <--
WO 9640135 19961219 <--
AI US 1997-973622 19971204 (8)
WO 1996-US9363 19960604
19971204 PCT 371 date
19971204 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-488267, filed on 7 Jun 1995,
now patented, Pat. No. US 5620993
DT Utility
FS Granted
LN.CNT 1225
INCL INCLM: 514/316.000
INCLS: 514/326.000; 546/187.000; 546/189.000; 546/191.000
NCL NCLM: 514/316.000
NCLS: 514/326.000; 546/187.000; 546/189.000; 546/191.000
IC [7]
ICM: A61K031-445
ICS: A61K031-4453; C07D211-06; C07D401-04
EXF 546/193; 546/213; 546/215; 546/217; 546/219; 546/221; 546/228; 546/234;
546/187; 546/189; 546/191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 66 USPATFULL on STN
AN 2000:54133 USPATFULL
TI Alpha 1a adrenergic receptor antagonists
IN Patane, Michael A., Harleysville, PA, United States
Bock, Mark G., Hatfield, PA, United States
Nagarathnam, Dhanapalan, Ramsey, NJ, United States
Lagu, Bharat, Maywood, NJ, United States
Wong, Wai C., Newark, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
Synaptic Pharmaceutical Corp., Paramus, NJ, United States (U.S.
corporation)
PI US 6057350 20000502 <--
AI US 1998-98781 19980617 (9)
PRAI US 1997-50136P 19970618 (60)
DT Utility
FS Granted
LN.CNT 2143
INCL INCLM: 514/376.000
INCLS: 514/373.000; 514/523.000; 548/210.000; 548/211.000; 548/229.000;

NCL NCLM: 548/230.000; 558/426.000
NCLS: 514/376.000
NCLS: 514/373.000; 514/523.000; 548/210.000; 548/211.000; 548/229.000;
548/230.000; 558/426.000

IC [7]
ICM: A61K031-42
ICS: A61K031-425; C07D263-22; C07D275-06

EXF 548/229; 548/230; 514/376

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 66 USPATFULL on STN

AN 2000:50838 USPATFULL

TI Heterocyclic vinyl ethers

IN Adam, Geo, Schopfheim, Germany, Federal Republic of
Kolczewski, Sabine, Lorrach, Germany, Federal Republic of
Mutel, Vincent, Mulhouse, France
Stadler, Heinz, Rheinfelden, Switzerland
Wichmann, Jurgen, Steinen, Germany, Federal Republic of
Woltering, Thomas Johannes, Weil am Rhein, Germany, Federal Republic of
Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

PA US 6054588 20000425 <--

AI US 1999-304624 19990504 (9)

RLI Division of Ser. No. US 1998-121737, filed on 23 Jul 1998

PRAI EP 1997-114065 19970814

DT Utility

FS Granted

LN.CNT 534

INCL INCLM: 548/252.000

NCL NCLM: 548/252.000

IC [7]

ICM: C07D257-04

EXF 548/252

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 66 USPATFULL on STN

AN 2000:47345 USPATFULL

TI Isolated human metabotropic glutamate receptor Mglur-8

IN Stormann, Thomas M., Salt Lake City, UT, United States

Simin, Rachel T., Salt Lake City, UT, United States

Hammerland, Lance G., Bountiful, UT, United States

Fuller, Forrest H., Salt Lake City, UT, United States

PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

PI US 6051688 20000418 <--

AI US 1997-823437 19970324 (8)

RLI Division of Ser. No. US 1996-604298, filed on 21 Feb 1996

DT Utility

FS Granted

LN.CNT 3301

INCL INCLM: 530/350.000

INCLS: 435/069.100; 536/023.500

NCL NCLM: 530/350.000

NCLS: 435/069.100; 536/023.500

IC [7]

ICM: C07K014-705

ICS: C12N015-12

EXF 435/69.1; 530/350; 576/23.5; 514/74

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 66 USPATFULL on STN

AN 2000:44099 USPATFULL

TI Morpholine and thiomorpholine tachykinin receptor antagonists

IN Dorn, Conrad P., Plainfield, NJ, United States

Finke, Paul E., Milltown, NJ, United States

Hale, Jeffrey J., Westfield, NJ, United States

Maccoss, Malcolm, Freehold, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States

Shah, Shrenik K., Metuchen, NJ, United States

Chambers, Mark Stuart, Harts, United Kingdom

Harrison, Timothy, Great Dunmow, United Kingdom

Ladduwahetty, Tamara, Buckhurst Hill, United Kingdom

Williams, Brian John, Great Dunmow, United Kingdom

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 6048859 20000411 <--

AI US 1999-251190 19990216 (9)

RLI Division of Ser. No. US 1997-959393, filed on 28 Oct 1997, now patented,

Pat. No. US 5872116 which is a division of Ser. No. US 1995-525259, filed on 8 Sep 1995, now patented, Pat. No. US 5719147 which is a continuation-in-part of Ser. No. WO 1994-US14497, filed on 13 Dec 1994 And Ser. No. US 1993-61194, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992, now abandoned

DT Utility
FS Granted
LN.CNT 8151
INCL INCLM: 514/227.500
INCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;
514/361.000; 514/362.000; 514/378.000; 514/385.000; 514/397.000;
514/403.000; 514/404.000; 514/411.000; 514/872.000
NCL NCLM: 514/227.500
NCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;
514/361.000; 514/362.000; 514/378.000; 514/385.000; 514/397.000;
514/403.000; 514/404.000; 514/411.000; 514/872.000
IC [7]
ICM: A61K031-54
ICS: A61K031-535; A61K031-53; A61K031-50; A61K031-41
EXF 514/227.5; 514/227.8; 514/231.2; 514/231.5; 514/241; 514/247; 514/361;
514/362; 514/378; 514/385; 514/397; 514/403; 514/404; 514/411; 514/872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 66 USPATFULL on STN
AN 2000:43951 USPATFULL
TI Human ***G*** - ***protein*** ***coupled*** ***receptor***
polynucleotides
IN Hinuma, Shuji, Ibaraki, Japan
Fukusumi, Shoji, Ibaraki, Japan
Kawamata, Yuji, Ibaraki, Japan
PA Takeda Chemical Industries, Ltd., Tsukuba Ibaraki, Japan (non-U.S.
corporation)
PI US 6048711 20000411 <--
AI US 1997-959381 19971028 (8)
PRAI JP 1996-286823 19961029
DT Utility
FS Granted
LN.CNT 2603
INCL INCLM: 435/069.100
INCLS: 536/023.500; 435/252.300; 435/254.110; 435/320.100; 435/325.000
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C12N015-09
ICS: C07K014-705
EXF 536/23.5; 435/69.1; 435/325; 435/252.3; 435/254.11; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 66 USPATFULL on STN
AN 2000:31434 USPATFULL
TI Administration of 5-HT.sub.3 receptor antagonists to treat premature
ejaculation
IN Smith, William L., Oakland, CA, United States
Doherty, Jr., Paul C., Cupertino, CA, United States
Place, Virgil A., Kawaihae, HI, United States
PA Vivus, Incorporated, Mountain View, CA, United States (U.S. corporation)
PI US 6037360 20000314 <--
AI US 1997-959061 19971028 (8)
DT Utility
FS Granted
LN.CNT 920
INCL INCLM: 514/397.000
INCLS: 514/415.000
NCL NCLM: 514/397.000
NCLS: 514/415.000
IC [7]
ICM: A61K031-415
ICS: A61K031-405
EXF 514/415; 514/397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 66 USPATFULL on STN
AN 2000:31428 USPATFULL
TI Alpha 1a adrenergic receptor antagonists

IN Patane, Michael A., Harleysville, PA, United States
Selnick, Harold G., Ambler, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6037354 20000314 <--
AI US 1998-99031 19980617 (9)
PRAI US 1997-49921P 19970618 (60)
DT Utility
FS Granted
LN.CNT 4142
INCL INCLM: 514/318.000
INCLS: 514/326.000; 514/369.000; 514/376.000; 546/194.000; 546/209.000;
548/228.000; 548/230.000; 548/183.000; 548/188.000; 548/189.000
NCL NCLM: 514/318.000
NCLS: 514/326.000; 514/369.000; 514/376.000; 546/194.000; 546/209.000;
548/183.000; 548/188.000; 548/189.000; 548/228.000; 548/230.000
IC [7]
ICM: C07D263-06
ICS: C07D263-04; C07D277-04; C07D413-12; A61K031-42
EXF 548/228; 548/230; 548/231; 548/183; 548/188; 548/189; 514/318; 514/326;
514/369; 514/376; 546/194; 546/209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 66 USPATFULL on STN
AN 2000:31414 USPATFULL
TI Synthesis and use of thiophene- and pyrrole-based heteroaromatic
compounds
IN Castelhana, Arlindo L., New City, NY, United States
McKibben, Bryan, White Plains, NY, United States
PA Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S.
corporation)
PI US 6037340 20000314 <--
AI US 1997-864240 19970528 (8)
DT Utility
FS Granted
LN.CNT 1896
INCL INCLM: 514/183.000
INCLS: 514/342.000; 514/422.000; 514/443.000; 514/447.000; 540/480.000;
540/596.000; 546/280.400; 548/527.000; 548/950.000; 548/962.000;
549/050.000; 549/068.000; 549/069.000
NCL NCLM: 514/183.000
NCLS: 514/342.000; 514/422.000; 514/443.000; 514/447.000; 540/480.000;
540/596.000; 546/280.400; 548/527.000; 548/950.000; 548/962.000;
549/050.000; 549/068.000; 549/069.000
IC [7]
ICM: A61K031-38
ICS: A61K031-40; A61K031-435; C07D205-02
EXF 514/443; 514/447; 549/68; 549/69; 549/50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 66 USPATFULL on STN
AN 2000:24677 USPATFULL
TI ***Calcium*** receptor-active molecules
IN Nemeth, Edward F., Salt Lake City, UT, United States
Van Wagenen, Bradford C., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.
corporation)
The Brigham and Women's Hospital, Boston, MA, United States (U.S.
corporation)
PI US 6031003 20000229 <--
AI US 1995-484719 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-353784, filed on 8 Dec 1994
which is a continuation-in-part of Ser. No. WO 1994-US12117, filed on 21
Oct 1994 Ser. No. Ser. No. US 1994-292827, filed on 19 Aug 1994, now
abandoned Ser. No. Ser. No. US 1993-141248, filed on 22 Oct 1993, now
abandoned And Ser. No. US 1993-9389, filed on 23 Feb 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1993-17127, filed on 12
Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US
1992-934161, filed on 21 Aug 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1992-834044, filed on 11 Feb 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1991-749451, filed on 23 Aug 1991, now abandoned
DT Utility

FS Granted
LN.CNT 8955
INCL INCLM: 514/579.000
INCLS: 514/614.000; 514/607.000; 514/646.000; 514/649.000
NCL NCLM: 514/579.000
NCLS: 514/607.000; 514/614.000; 514/646.000; 514/649.000
IC [7]
ICM: A61K031-44
ICS: A61K031-135; A01N033-02; A01N037-18
EXF 514/2; 514/614; 514/579; 514/607; 514/646; 514/649
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 66 USPATFULL on STN
AN 2000:9879 USPATFULL
TI Azole peptidomimetics as thrombin receptor antagonists
IN Hoekstra, William, Villanova, PA, United States
Hulshizer, Becky L., North Wales, PA, United States
PA Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)
PI US 6017890 20000125 <--
AI US 1999-245739 19990208 (9)
DT Utility
FS Granted
LN.CNT 742
INCL INCLM: 514/019.000
INCLS: 514/002.000; 514/018.000; 530/330.000; 530/331.000; 548/146.000; 548/215.000; 548/333.500; 548/335.100
NCL NCLM: 514/019.000
NCLS: 514/002.000; 514/018.000; 530/330.000; 530/331.000; 548/146.000; 548/215.000; 548/333.500; 548/335.100
IC [6]
ICM: A61K038-00
ICS: C07K005-00
EXF 514/2; 514/18-19; 530/300; 530/331; 548/146; 548/215; 548/333.5; 548/335.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 66 USPATFULL on STN
AN 2000:1911 USPATFULL
TI ***Calcium*** receptor-active molecules
IN Nemeth, Edward F., Salt Lake City, UT, United States
Van Wagenen, Bradford C., Salt Lake City, UT, United States
Balandrin, Manuel F., Sandy, UT, United States
DelMar, Eric G., Salt Lake City, UT, United States
Moe, Scott T., Salt Lake City, UT, United States
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)
The Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6011068 20000104 <--
AI US 1994-353784 19941208 (8)
RLI Continuation-in-part of Ser. No. WO 1994-US12117, filed on 21 Oct 1994
And a continuation-in-part of Ser. No. US 1994-292827, filed on 19 Aug 1994, now abandoned
And a continuation-in-part of Ser. No. US 1993-141248, filed on 22 Oct 1993, now abandoned
And a continuation-in-part of Ser. No. US 1993-9389, filed on 23 Feb 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1993-17127, filed on 12 Feb 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1992-934161, filed on 21 Aug 1992, now abandoned
which is a continuation-in-part of Ser. No. US 1992-834044, filed on 11 Feb 1992, now abandoned
which is a continuation-in-part of Ser. No. US 1991-749451, filed on 23 Aug 1991, now abandoned
DT Utility
FS Granted
LN.CNT 7466
INCL INCLM: 514/654.000
INCLS: 564/337.000; 564/366.000; 564/374.000; 564/384.000; 564/389.000
NCL NCLM: 514/654.000
NCLS: 564/337.000; 564/366.000; 564/374.000; 564/384.000; 564/389.000
IC [6]
ICM: A61K031-195
ICS: C07C211-00; C07C213-00
EXF 564/337; 564/366; 564/374; 564/384; 564/389; 514/654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 66 USPATFULL on STN

AN 1999:160238 USPATFULL
TI 5-HT.sub.1F agonists intermediates
IN Filla, Sandra Ann, Indianapolis, IN, United States
Johnson, Kirk W., Carmel, IN, United States
Phebus, Lee A., Fountaintown, IN, United States
Schaus, John Mehnert, Zionsville, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 5998622 19991207 <--
AI US 1998-112562 19980709 (9)
RLI Division of Ser. No. US 1997-969851, filed on 14 Nov 1997, now patented,
Pat. No. US 5817671
PRAI US 1996-30950P 19961115 (60)
DT Utility
FS Granted
LN.CNT 2732
INCL INCLM: 546/113.000
INCLS: 544/127.000
NCL NCLM: 546/113.000
NCLS: 544/127.000
IC [6]
ICM: C07D471-04
EXF 546/113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 66 USPATFULL on STN
AN 1999:141602 USPATFULL
TI Chimeric receptors and methods for identifying compounds active at
metabotropic glutamate receptors
IN Fuller, Forrest H., La Jolla, CA, United States
Krapcho, Karen J., Salt Lake City, UT, United States
Hammerland, Lance G., Bountiful, UT, United States
PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.
corporation)
PI US 5981195 19991109 <--
AI US 1996-687289 19960725 (8)
PRAI US 1995-1526P 19950726 (60)
DT Utility
FS Granted
LN.CNT 4472
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/069.700; 435/252.300; 435/320.100; 530/350.000;
536/023.400
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/069.700; 435/252.300; 435/320.100; 530/350.000;
536/023.400
IC [6]
ICM: C07K019-00
ICS: C12N015-62
EXF 435/69.7; 435/6; 435/7.1; 435/7.2; 435/252.3; 435/32.7; 530/350;
536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 66 USPATFULL on STN
AN 1999:137264 USPATFULL
TI Alpha 1a adrenergic receptor antagonists
IN Patane, Michael A., Harleysville, PA, United States
Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Landsdale, PA, United States
Ponticello, Rose Ann, Harleysville, PA, United States
Newton, Randall C., West Point, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5977115 19991102 <--
WO 9640136 19961219 <--
AI US 1997-973624 19971204 (8)
WO 1996-US9425 19960606
19971204 PCT 371 date
19971204 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-488272, filed on 7 Jun 1995,
now patented, Pat. No. US 5403874
DT Utility
FS Granted
LN.CNT 2740
INCL INCLM: 514/255.000
INCLS: 544/358.000; 544/360.000; 544/366.000; 544/367.000; 544/372.000;
544/392.000; 544/393.000; 544/396.000; 544/400.000; 544/405.000

NCL NCLM: 514/252.110
NCLS: 514/235.800; 514/252.130; 514/253.010; 514/253.090; 514/254.010;
514/254.100; 514/255.030; 544/358.000; 544/360.000; 544/366.000;
544/367.000; 544/372.000; 544/392.000; 544/393.000; 544/396.000;
544/400.000; 544/405.000

IC [6]
ICM: A61K031-495
ICS: C07D295-12

EXF 544/358; 544/360; 544/366; 544/367; 544/372; 544/392; 544/393; 544/396;
544/400; 544/405; 514/255

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 66 USPATFULL on STN

AN 1999:132773 USPATFULL

TI Methods of treating nueropeptide Y-associated conditions

IN Bue-Valleskey, Juliana Maude, Indianapolis, IN, United States

Heiman, Mark Louis, Indianapolis, IN, United States

Stephens, Thomas Wesley, Indianapolis, IN, United States

Tinsley, Frank C., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)

PI US 5972888 19991026 <--

AI US 1997-959112 19971023 (8)

RLI Continuation of Ser. No. US 1996-672897, filed on 28 Jun 1996, now
abandoned

PRAI US 1995-737P 19950630 (60)

US 1995-861P 19950630 (60)

DT Utility

FS Granted

LN.CNT 3222

INCL INCLM: 514/012.000

INCLS: 530/324.000; 546/202.000

NCL NCLM: 514/012.000

NCLS: 530/324.000; 546/202.000

IC [6]

ICM: A61K038-00

ICS: C07K014-00

EXF 514/12; 514/324; 514/909; 546/202; 530/324; 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 66 USPATFULL on STN

AN 1999:121216 USPATFULL

TI ***Calcium*** receptor-active molecules

IN Brown, Edward M., Milton, MA, United States

Hebert, Steven C., Wellesley, MA, United States

Garrett, Jr., James E., Salt Lake City, UT, United States

PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.
corporation)

Brigham and Women's Hospital, Boston, MA, United States (U.S.
corporation)

PI US 5962314 19991005 <--

AI US 1997-943986 19971003 (8)

RLI Continuation of Ser. No. US 1995-484565, filed on 7 Jun 1995, now
patented, Pat. No. US 5763569 which is a continuation-in-part of Ser.
No. US 1994-353784, filed on 8 Dec 1994 which is a continuation-in-part
of ser. No. WO 1994-US12117, filed on 21 Oct 1994 Ser. No. Ser. No. US
1994-292827, filed on 19 Aug 1994, now abandoned Ser. No. Ser. No. US
1993-141248, filed on 22 Oct 1993, now abandoned And Ser. No. US
1993-9389, filed on 23 Feb 1993, now abandoned

DT Utility

FS Granted

LN.CNT 7882

INCL INCLM: 435/320.100

INCLS: 435/325.000; 435/243.000; 435/252.300; 536/023.100; 536/023.400;
536/023.500; 536/024.310; 530/300.000; 530/326.000; 530/350.000

NCL NCLM: 435/320.100

NCLS: 435/243.000; 435/252.300; 435/325.000; 530/300.000; 530/326.000;
530/350.000; 536/023.100; 536/023.400; 536/023.500; 536/024.310

IC [6]

ICM: C12N015-63

ICS: C12N015-11; C12N015-12; C07K007-00

EXF 435/69.1; 435/252.3; 435/320.1; 435/325; 435/243; 536/23.1; 536/23.4;
536/23.5; 536/24.31; 530/300; 530/326; 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 66 USPATFULL on STN

AN 1999:117502 USPATFULL
TI Phenyl-substituted 5H-thiazolo[3,2-A]pyrimidine derivative glutamate
receptor antagonists
IN Adam, Geo, Schopfheim, Germany, Federal Republic of
Kolczewski, Sabine, Lorrach, Germany, Federal Republic of
Mutel, Vincent, Mulhouse, France
Wichmann, Jurgen, Steinen, Germany, Federal Republic of
Woltering, Thomas Johannes, Weil am Rhein, Germany, Federal Republic of
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 5958931 19990928 <--
AI US 1998-115191 19980714 (9)
PRAI EP 1997-112324 19970718
DT Utility
FS Granted
LN.CNT 816
INCL INCLM: 514/258.000
INCLS: 544/278.000
NCL NCLM: 514/259.200
NCLS: 544/278.000
IC [6]
ICM: A61K031-505
ICS: C07D513-04
EXF 514/258; 544/278; 544/282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 66 USPATFULL on STN
AN 1999:117455 USPATFULL
TI Compositions and methods for treating erectile dysfunction
IN Kifor, Imre, Methuen, MA, United States
Williams, Gordon, Belmont, MA, United States
PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S.
corporation)
PI US 5958884 19990928 <--
AI US 1998-47594 19980325 (9)
PRAI US 1997-41875P 19970411 (60)
DT Utility
FS Granted
LN.CNT 692
INCL INCLM: 514/016.000
INCLS: 514/048.000; 514/381.000; 514/396.000; 514/397.000; 514/400.000
NCL NCLM: 514/016.000
NCLS: 514/048.000; 514/381.000; 514/396.000; 514/397.000; 514/400.000
IC [6]
ICM: A61K031-41
ICS: A61K031-70; A61K038-08
EXF 514/16; 514/48; 514/381; 514/396; 514/397; 514/400; 530/316; 548/252;
548/253; 548/312.7; 548/323.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 66 USPATFULL on STN
AN 1999:110340 USPATFULL
TI Alpha 1a adrenergic receptor antagonists
IN Evans, Ben E., Lansdale, PA, United States
Ponticello, Gerald S., Lansdale, PA, United States
Hoffman, Jacob M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5952351 19990914 <--
WO 9625934 19960829 <--
AI US 1997-860314 19970813 (8)
WO 1996-US2534 19960223
19970813 PCT 371 date
19970813 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-392699, filed on 23 Feb 1995,
now abandoned
DT Utility
FS Granted
LN.CNT 2602
INCL INCLM: 514/321.000
INCLS: 514/322.000; 546/198.000; 546/199.000
NCL NCLM: 514/321.000
NCLS: 514/322.000; 546/198.000; 546/199.000
IC [6]
ICM: A61K031-445
ICS: C07D413-14
EXF 514/321; 514/322; 546/198; 546/199
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 43 OF 66 USPATFULL on STN
 AN 1999:78727 USPATFULL
 TI Alpha 1a adrenergic receptor antagonists
 IN Bock, Mark G., Hatfield, PA, United States
 Patane, Michael A., Harleysville, PA, United States
 Ponticello, Rose Ann, Madison, NJ, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5922722 19990713 <--
 WO 9717967 19970522 <--
 AI US 1998-66477 19980422 (9)
 WO 1996-US18321 19961112
 19980422 PCT 371 date
 19980422 PCT 102(e) date
 DT Utility
 FS Granted
 LN.CNT 1397
 INCL INCLM: 514/255.000
 INCLS: 514/318.000
 NCL NCLM: 514/253.010
 NCLS: 514/255.010; 514/255.020; 514/255.030; 514/318.000
 IC [6]
 ICM: A61K031-445
 EXF 514/255; 514/318
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 44 OF 66 USPATFULL on STN
 AN 1999:78711 USPATFULL
 TI Morpholine and thiomorpholine tachykinin receptor antagonists
 IN Dorn, Conrad P., Plainfield, NJ, United States
 Hale, Jeffrey J., Westfield, NJ, United States
 Maccoss, Malcolm, Freehold, NJ, United States
 Mills, Sander G., Woodbridge, NJ, United States
 Shah, Shrenik K., Metuchen, NJ, United States
 Ladduwahetty, Tamara, Buckhurst Hill, United Kingdom
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5922706 19990713 <--
 AI US 1997-969685 19971113 (8)
 RLI Division of Ser. No. US 1995-525259, filed on 5 Sep 1995, now patented,
 Pat. No. US 5719147 which is a continuation-in-part of Ser. No. WO
 1994-US14497, filed on 13 Dec 1994 And Ser. No. US 1993-169889, filed on
 17 Dec 1993, now abandoned which is a continuation-in-part of Ser. No.
 US 1993-61914, filed on 19 May 1993, now abandoned which is a
 continuation-in-part of Ser. No. US 1992-971448, filed on 4 Nov 1992,
 now abandoned which is a continuation-in-part of Ser. No. US
 1992-905976, filed on 29 Jun 1992, now abandoned
 DT Utility
 FS Granted
 LN.CNT 7932
 INCL INCLM: 514/227.500
 INCLS: 514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500;
 514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;
 514/236.800; 514/237.200; 544/059.000; 544/060.000; 544/062.000;
 544/058.100; 544/058.400; 544/106.000; 544/111.000; 544/114.000;
 544/122.000; 544/128.000; 544/129.000; 544/132.000; 544/133.000;
 544/137.000; 544/139.000; 544/140.000; 544/141.000; 544/143.000;
 544/145.000; 544/146.000; 544/148.000; 544/152.000; 544/153.000
 NCL NCLM: 514/227.500
 NCLS: 514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500;
 514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;
 514/236.800; 514/237.200; 544/058.100; 544/058.400; 544/059.000;
 544/060.000; 544/062.000; 544/106.000; 544/111.000; 544/114.000;
 544/122.000; 544/128.000; 544/129.000; 544/132.000; 544/133.000;
 544/137.000; 544/139.000; 544/140.000; 544/141.000; 544/143.000;
 544/145.000; 544/146.000; 544/148.000; 544/152.000; 544/153.000
 IC [6]
 ICM: C07D413-04
 ICS: C07D417-04; C07D279-12; C07D265-30; A61K031-54; A61K031-535
 EXF 544/59-62; 544/58.1; 544/58.4; 544/106; 544/111; 544/114; 544/122;
 544/128-153; 514/227.5; 514/227.8; 514/228.2; 514/228.5; 514/236.2;
 514/236.5; 514/233.8; 514/233.5; 514/231.2; 514/231.5; 514/236.8;
 514/235.8; 514/237.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 45 OF 66 USPATFULL on STN
 AN 1999:75792 USPATFULL

TI Nitropyridine compound
IN Filla, Sandra Ann, Indianapolis, IN, United States
Johnson, Kirk W., Carmel, IN, United States
Phebus, Lee A., Fountaintown, IN, United States
Schaus, John Mehnert, Zionsville, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 5919936 19990706 <--
AI US 1998-112560 19980709 (9)
RLI Division of Ser. No. US 1997-969851, filed on 14 Nov 1997
PRAI US 1996-30950P 19961115 (60)
DT Utility
FS Granted
LN.CNT 2734
INCL INCLM: 546/308.000
NCL NCLM: 546/308.000
IC [6]
ICM: C07D213-76
EXF 546/308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 46 OF 66 USPATFULL on STN
AN 1999:59074 USPATFULL
TI 5-HT.sub.IF -agonists effective in treating migraine
IN Filla, Sandra A., Franklin, IN, United States
Mathes, Brian M., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 5905084 19990518 <--
AI US 1997-970637 19971114 (8)
DT Utility
FS Granted
LN.CNT 1541
INCL INCLM: 514/300.000
INCLS: 546/113.000
NCL NCLM: 514/300.000
NCLS: 546/113.000
IC [6]
ICM: A61K031-44
ICS: C07D047-02
EXF 514/300; 546/113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 47 OF 66 USPATFULL on STN
AN 1999:27762 USPATFULL
TI Antisense oligonucleotides against JNK
IN McKay, Robert, La Mesa, CA, United States
Dean, Nicholas M., Encinitas, CA, United States
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S.
corporation)
PI US 5877309 19990302 <--
AI US 1997-910629 19970813 (8)
DT Utility
FS Granted
LN.CNT 3556
INCL INCLM: 536/024.500
INCLS: 435/006.000; 435/091.100; 435/172.100; 435/371.000; 435/375.000;
536/023.100; 536/024.300; 536/024.500
NCL NCLM: 536/024.500
NCLS: 435/006.000; 435/091.100; 435/371.000; 435/375.000; 536/023.100;
536/024.300
IC [6]
ICM: C07H021-04
ICS: C12Q001-68; C12N015-85
EXF 536/24.5; 536/24.3; 536/23.2; 536/23.1; 514/44; 435/320.1; 435/371;
435/16; 435/375; 435/91.1; 435/172.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 48 OF 66 USPATFULL on STN
AN 1999:22097 USPATFULL
TI Morpholine and thiomorpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
Finke, Paul E., Milltown, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
Maccoss, Malcolm, Freehold, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States
 Shah, Shrenik K., Metuchen, NJ, United States
 Chambers, Mark Stuart, Watford, England
 Harrison, Timothy, Great Dunmow, England
 Ladduwahetty, Tamara, Buckhurst Hill, England
 Williams, Brian John, Great Dunmow, England
 Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PA US 5872116 19990216 <--
 PI US 1997-959393 19971028 (8)
 AI
 RLI Division of Ser. No. US 1995-525259, filed on 8 Sep 1995, now patented,
 Pat. No. US 5719147 And a continuation-in-part of Ser. No. US
 1993-169889, filed on 17 Dec 1993, now abandoned which is a
 continuation-in-part of Ser. No. US 1993-61914, filed on 19 May 1993,
 now abandoned which is a continuation-in-part of Ser. No. US
 1992-971448, filed on 4 Nov 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 8249
 INCL INCLM: 514/227.500
 INCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;
 514/361.000; 514/362.000; 514/363.000; 514/378.000; 514/397.000;
 514/825.000
 NCL NCLM: 514/227.500
 NCLS: 514/227.800; 514/231.200; 514/231.500; 514/241.000; 514/247.000;
 514/361.000; 514/362.000; 514/363.000; 514/378.000; 514/397.000;
 514/825.000
 IC [6]
 ICM: A61K031-54
 ICS: A61K031-535; A61K031-53; A61K031-50
 EXF 514/227.5; 514/227.8; 514/231.2; 514/231.5; 514/241; 514/247; 514/361;
 514/362; 514/363; 514/378; 514/397; 514/825
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 49 OF 66 USPATFULL on STN
 AN 1999:4350 USPATFULL
 TI Method of screening ***calcium*** receptor-active molecules
 IN Nemeth, Edward F., Salt Lake City, UT, United States
 Brown, Edward M., Milton, MA, United States
 Hebert, Steven C., Wellesley, MA, United States
 Garrett, Jr., James E., Salt Lake City, UT, United States
 Van Wagenen, Bradford C., Salt Lake City, UT, United States
 Balandrin, Manuel F., Sandy, UT, United States
 Del Mar, Eric G., Salt Lake City, UT, United States
 PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S.
 corporation)
 NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.
 corporation)
 PI US 5858684 19990112 <--
 AI US 1995-480751 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-353784, filed on 8 Dec 1994
 which is a continuation-in-part of Ser. No. US 1994-292827, filed on 19
 Aug 1994, now abandoned And a continuation-in-part of Ser. No. US
 1993-141248, filed on 22 Oct 1993, now abandoned And a
 continuation-in-part of Ser. No. US 1993-9389, filed on 23 Feb 1993, now
 abandoned which is a continuation-in-part of Ser. No. US 1993-17127,
 filed on 12 Feb 1993, now abandoned which is a continuation-in-part of
 Ser. No. US 1992-934161, filed on 21 Aug 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1992-834044, filed on 11 Feb 1992,
 now abandoned which is a continuation-in-part of Ser. No. US
 1991-749451, filed on 23 Aug 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 7588
 INCL INCLM: 435/007.200
 INCLS: 435/065.100; 435/325.000; 435/252.300; 435/320.100; 435/007.100;
 530/300.000; 530/324.000; 530/350.000; 536/023.100; 536/023.500
 NCL NCLM: 435/007.200
 NCLS: 435/007.100; 435/069.100; 435/252.300; 435/320.100; 435/325.000;
 530/300.000; 530/324.000; 530/350.000; 536/023.100; 536/023.500
 IC [6]
 ICM: C12Q001-68
 EXF 435/7.2; 435/65.1; 435/325; 435/252.3; 435/320.1; 530/300; 530/350;
 530/324; 536/23.1; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 50 OF 66 USPATFULL on STN
 AN 1998:122422 USPATFULL
 TI 5-HT.sub.1F agonists
 IN Filla, Sandra Ann, Indianapolis, IN, United States
 Johnson, Kirk W., Carmel, IN, United States
 Phebus, Lee A., Fountaintown, IN, United States
 Schaus, John Mehnert, Zionsville, IN, United States
 PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 5817671 19981006 <--
 AI US 1997-969851 19971114 (8)
 PRAI US 1996-30950P 19961115 (60)
 DT Utility
 FS Granted
 LN.CNT 2947
 INCL INCLM: 514/300.000
 INCLS: 544/058.400; 544/127.000; 546/113.000
 NCL NCLM: 514/300.000
 NCLS: 544/058.400; 544/127.000; 546/113.000
 IC [6]
 ICM: A61K031-44
 ICS: C07D471-04
 EXF 546/113; 514/300
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 51 OF 66 USPATFULL on STN
 AN 1998:111936 USPATFULL
 TI Alpha 1a adrenergic receptor antagonist
 IN Bock, Marg G., Hatfield, PA, United States
 Patane, Michael A., Harleysville, PA, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5807856 19980915 <--
 AI US 1996-747687 19961112 (8)
 PRAI US 1995-7964P 19951115 (60)
 DT Utility
 FS Granted
 LN.CNT 1306
 INCL INCLM: 514/252.000
 INCLS: 514/171.000; 514/253.000; 514/255.000; 544/360.000; 544/364.000;
 544/368.000; 544/379.000; 544/393.000; 544/388.000; 544/389.000;
 544/390.000; 544/384.000; 544/385.000
 NCL NCLM: 514/252.130
 NCLS: 514/171.000; 514/253.010; 514/253.120; 514/254.100; 514/255.010;
 514/255.020; 514/255.030; 544/360.000; 544/364.000; 544/368.000;
 544/379.000; 544/384.000; 544/385.000; 544/388.000; 544/389.000;
 544/390.000; 544/393.000
 IC [6]
 ICM: A61K031-495
 ICS: A61K031-58; C07D241-04; C07D417-06
 EXF 544/393; 544/360; 544/379; 544/364; 544/384-385; 544/388-390; 514/255;
 514/252; 514/171
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 52 OF 66 USPATFULL on STN
 AN 1998:82768 USPATFULL
 TI Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
 IN Jacobson, Marlene A., Elkins Park, PA, United States
 Norton, Richard, Somerset, NJ, United States
 Chakravarty, Prasun K., Edison, NJ, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5780481 19980714 <--
 AI US 1996-694061 19960808 (8)
 DT Utility
 FS Granted
 LN.CNT 912
 INCL INCLM: 514/293.000
 INCLS: 514/294.000; 514/359.000; 514/461.000
 NCL NCLM: 514/293.000
 NCLS: 514/294.000; 514/359.000; 514/461.000
 IC [6]
 ICM: A61K031-44
 ICS: A61K031-41; A61K031-34
 EXF 514/293; 514/294; 514/359; 514/461
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 53 OF 66 USPATFULL on STN
 AN 1998:82754 USPATFULL
 TI Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
 IN Dorn, Conrad P., Plainfield, NJ, United States
 Hale, Jeffrey J., Westfield, NJ, United States
 Maccoss, Malcolm, Freehold, NJ, United States
 Mills, Sander G., Woodbridge, NJ, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5780467 19980714 <--
 AI US 1997-907738 19970808 (8)
 RLI Division of Ser. No. US 1995-525870, filed on 8 Sep 1995, now patented, Pat. No. US 5691336 which is a continuation-in-part of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 7260
 INCL INCLM: 514/236.200
 INCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800
 NCL NCLM: 514/236.200
 NCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800
 IC [6]
 ICM: A61K031-535
 EXF 514/235.2; 514/235.5; 514/235.8; 514/233.5; 514/236.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 54 OF 66 USPATFULL on STN
 AN 1998:79171 USPATFULL
 TI Naphthimidazolyl neuropeptide Y receptor antagonists
 IN Nunes, Anne Marie, Andover, MA, United States
 Zarrinmayeh, Hamideh, Carmel, IN, United States
 PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 5776931 19980707 <--
 AI US 1997-775533 19970109 (8)
 DT Utility
 FS Granted
 LN.CNT 1892
 INCL INCLM: 514/232.800
 INCLS: 514/322.000; 514/393.000; 514/394.000; 514/395.000; 544/139.000; 546/199.000; 548/302.100
 NCL NCLM: 514/232.800
 NCLS: 514/322.000; 514/393.000; 514/394.000; 514/395.000; 544/139.000; 546/199.000; 548/302.100
 IC [6]
 ICM: A61K031-535
 ICS: A61K031-445; A61K031-415; C09D413-00; C09D421-00; C09D235-02
 EXF 514/322; 514/232.8; 514/393; 514/394; 514/395; 548/302.1; 544/139; 546/199
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 55 OF 66 USPATFULL on STN
 AN 1998:61669 USPATFULL
 TI Alpha IC adrenergic receptor antagonists
 IN Huff, Joel R., Gwynedd Valley, PA, United States
 Lee, Hee-Yoon, Yusung-Gu, Korea, Republic of
 Nerenberg, Jennie B., Maple Glen, PA, United States
 Thompson, Wayne J., Lansdale, PA, United States
 Bell, Ian M., Harleysville, PA, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5760054 19980602 <--
 WO 9528397 19951026 <--
 AI US 1996-722001 19961001 (8)
 WO 1995-US4590 19950413
 19961001 PCT 371 date
 19961001 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1994-229276, filed on 13 Apr 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 4070
 INCL INCLM: 514/302.000
 INCLS: 514/321.000; 514/322.000; 514/324.000; 546/114.000; 546/198.000; 546/199.000; 546/202.000
 NCL NCLM: 514/302.000

NCLS: 514/321.000; 514/322.000; 514/324.000; 546/114.000; 546/198.000;
546/199.000; 546/202.000

IC [6]

ICM: A61K031-445

ICS: C07D401-04; C07D471-04; C07D471-10

EXF 514/322; 514/324; 514/321; 514/302; 546/114; 546/198; 546/199; 546/202;
546/115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 56 OF 66 USPATFULL on STN

AN 1998:48408 USPATFULL

TI Alpha 1b adrenergic receptor antagonists

IN Bock, Mark G., Hatfield, PA, United States

Patane, Michael A., Harleysville, PA, United States

Lumma, William C., Pennsburg, PA, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5747490 19980505 <--

AI US 1996-716041 19960919 (8)

PRAI US 1995-4501P 19950929 (60)

DT Utility

FS Granted

LN.CNT 1407

INCL INCLM: 514/233.800

INCLS: 514/255.000; 514/260.000; 544/116.000; 544/291.000

NCL NCLM: 514/233.800

NCLS: 514/252.170; 514/266.200; 514/266.220; 514/266.230; 544/116.000;
544/291.000

IC [6]

ICM: A61K031-535

ICS: A01N043-60; C07D415-00; C07D239-72

EXF 544/116; 544/291; 514/233.8; 514/255; 514/260

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 57 OF 66 USPATFULL on STN

AN 1998:17310 USPATFULL

TI Morpholine and thiomorpholine tachykinin receptor antagonists

IN Dorn, Conrad P., Plainfield, NJ, United States

Finke, Paul E., Milltown, NJ, United States

Hale, Jeffrey J., Westfield, NJ, United States

MacCoss, Malcolm, Freehold, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States

Shah, Shrenik K., Metuchen, NJ, United States

Chambers, Mark Stuart, North Bushey, England

Harrison, Timothy, Great Dunmow, England

Ladduwahetty, Tamara, Buckhurst Hill, England

Williams, Brian John, Great Dunmow, England

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5719147 19980217 <--

AI US 1995-525259 19950908 (8)

RLI Continuation-in-part of Ser. No. US 1993-169889, filed on 17 Dec 1993,
now abandoned which is a continuation-in-part of Ser. No. US 1993-61914,
filed on 19 May 1993, now abandoned which is a continuation-in-part of
Ser. No. US 1992-971448, filed on 4 Nov 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,
now abandoned

DT Utility

FS Granted

LN.CNT 8352

INCL INCLM: 514/227.500

INCLS: 514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500;
514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;
514/236.800; 514/237.200; 544/059.000; 544/060.000; 544/061.000;
544/062.000; 544/058.100; 544/058.400; 544/111.000; 544/106.000;
544/114.000; 544/122.000; 544/128.000; 544/129.000; 544/132.000;
544/133.000; 544/137.000; 544/139.000; 544/140.000; 544/141.000;
544/143.000; 544/145.000; 544/146.000; 544/148.000; 544/152.000;
544/153.000

NCL NCLM: 514/227.500

NCLS: 514/227.800; 514/228.200; 514/231.200; 514/231.500; 514/233.500;
514/233.800; 514/235.200; 514/235.800; 514/236.200; 514/236.500;
514/236.800; 514/237.200; 544/058.100; 544/058.400; 544/059.000;
544/060.000; 544/061.000; 544/062.000; 544/106.000; 544/111.000;
544/114.000; 544/122.000; 544/128.000; 544/129.000; 544/132.000;
544/133.000; 544/137.000; 544/139.000

IC [6]

ICM: A61K031-54

EXF ICS: A61K031-535; C07D413-04; C07D417-04; C07D279-12; C07D265-30
514/236.2; 514/235.5; 514/235.8; 514/236.8; 514/237.2; 514/227.5;
514/227.8; 514/228.2; 514/231.2; 514/231.5; 514/233.5; 514/233.8;
514/236.5; 544/59; 544/60; 544/177; 544/158; 544/61; 544/62; 544/58.1;
544/58.4; 544/106; 544/111; 544/114; 544/122; 544/128; 544/129; 544/132;
544/133; 544/137; 544/139; 544/140; 544/141; 544/143; 544/145; 544/146;
544/148; 544/152; 544/153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 58 OF 66 USPATFULL on STN
AN 1998:14789 USPATFULL
TI Treatment of migraine with morpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
MacCoss, Malcolm, Freehold, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5716942 19980210 <--
AI US 1995-450198 19950525 (8)
RLI Division of Ser. No. US 1994-206771, filed on 4 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 6755
INCL INCLM: 514/090.000
INCLS: 514/235.500; 514/236.200
NCL NCLM: 514/090.000
NCLS: 514/235.500; 514/236.200
IC [6]
ICM: A61K031-675
ICS: A61K031-535
EXF 514/90; 514/235.5; 514/236.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 59 OF 66 USPATFULL on STN
AN 97:109895 USPATFULL
TI Morpholine compounds are prodrugs useful as tachykinin receptor
antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
MacCoss, Malcolm, Freehold, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5691336 19971125 <--
AI US 1995-525870 19950908 (8)
RLI Continuation-in-part of Ser. No. US 1994-206771, filed on 4 Mar 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 7292
INCL INCLM: 514/236.200
INCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800; 544/132.000;
544/134.000; 544/139.000; 544/141.000; 544/143.000
NCL NCLM: 514/236.200
NCLS: 514/233.500; 514/235.200; 514/235.500; 514/235.800; 544/132.000;
544/134.000; 544/139.000; 544/141.000; 544/143.000
IC [6]
ICM: C07D265-32
ICS: C07D279-12; C07D413-04; C07D413-06; C07D413-14
EXF 544/132; 544/134; 544/139; 544/141; 544/143; 514/235.2; 514/235.5;
514/235.8; 514/233.5; 514/236.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 60 OF 66 USPATFULL on STN
AN 97:107219 USPATFULL
TI ***Calcium*** receptor-active molecules
IN Brown, Edward M., Milton, MA, United States
Fuller, Forrest H., Salt Lake City, UT, United States
Hebert, Steven C., Wellesley, MA, United States
Garrett, Jr., James E., Salt Lake City, UT, United States
PA The Brigham & Women's Hospital, Inc., Boston, MA, United States (U.S.
corporation)
NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.
corporation)
PI US 5688938 19971118 <--
AI US 1995-485588 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-353784, filed on 8 Dec 1994

which is a continuation-in-part of Ser. No. US 1993-9389, filed on 23 Feb 1993, now abandoned Ser. No. US 1993-141248, filed on 22 Oct 1993, now abandoned And Ser. No. US 1994-292827, filed on 19 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US -141248 which is a continuation-in-part of Ser. No. US -9389 which is a continuation-in-part of Ser. No. US 1993-17127, filed on 12 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-934161, filed on 21 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-834044, filed on 11 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-749451, filed on 23 Aug 1991, now abandoned

DT Utility
FS Granted
LN.CNT 6522
INCL INCLM: 536/023.500
INCLS: 435/069.100; 435/007.100; 435/290.100; 435/252.300; 435/320.100;
530/300.000; 530/350.000; 530/324.000; 530/326.000; 536/023.100;
536/024.310
NCL NCLM: 536/023.500
NCLS: 435/007.100; 435/069.100; 435/252.300; 435/320.100; 530/300.000;
530/324.000; 530/326.000; 530/350.000; 536/023.100; 536/024.310
IC [6]
ICM: C07K004-705
ICS: C12N015-12
EXF 435/7.1; 435/69.1; 435/240.1; 435/252.3; 435/320.1; 535/23.5; 535/23.1;
530/300; 530/350; 530/324; 530/326; 530/327; 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 61 OF 66 USPATFULL on STN
AN 97:83974 USPATFULL
TI Alpha1a adrenergic receptor antagonists
IN Payne, Linda S., Lansdale, PA, United States
Young, Steven D., Lansdale, PA, United States
Zaborowski, Mary Jo L., Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5668148 19970916 <--
AI US 1995-425969 19950420 (8)
DT Utility
FS Granted
LN.CNT 2240
INCL INCLM: 514/314.000
INCLS: 514/307.000; 514/318.000; 514/321.000; 514/322.000; 514/323.000;
514/324.000; 514/326.000; 514/367.000; 514/372.000; 514/373.000;
514/375.000; 514/378.000; 514/379.000; 514/394.000; 514/406.000;
546/139.000; 546/167.000; 546/193.000; 546/194.000; 546/196.000;
546/197.000; 546/198.000; 546/199.000; 546/201.000; 546/202.000;
546/205.000; 546/211.000; 548/152.000; 548/159.000; 548/206.000;
548/207.000; 548/217.000; 548/241.000; 548/247.000; 548/306.100;
548/361.100; 548/364.100; 548/364.400; 548/365.700
NCL NCLM: 514/314.000
NCLS: 514/307.000; 514/318.000; 514/321.000; 514/322.000; 514/323.000;
514/324.000; 514/326.000; 514/367.000; 514/372.000; 514/373.000;
514/375.000; 514/378.000; 514/379.000; 514/394.000; 514/406.000;
546/139.000; 546/167.000; 546/193.000; 546/194.000; 546/196.000;
546/197.000; 546/198.000; 546/199.000; 546/201.000; 546/202.000;
546/205.000; 546/211.000; 548/152.000; 548/159.000; 548/206.000;
548/207.000; 548/217.000; 548/241.000; 548/247.000; 548/306.100;
548/361.100; 548/364.100; 548/364.400; 548/365.700
IC [6]
ICM: A61K031-47
ICS: A61K031-415; A61K031-42; A61K031-425; A61K031-445; C07D401-04;
C07D409-04
EXF 546/167; 546/194; 546/197; 546/211; 546/139; 546/193; 546/196; 546/198;
546/199; 546/201; 546/202; 546/205; 574/314; 574/318; 574/321; 574/326;
574/307; 574/322; 574/323; 574/324; 574/367; 574/372; 574/373; 574/375;
574/378; 574/379; 574/394; 574/406; 548/152; 548/159; 548/207; 548/217;
548/241; 548/306.1; 548/361; 548/364.1; 548/364.4; 548/365.7; 548/206;
548/247
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 62 OF 66 USPATFULL on STN
AN 97:76145 USPATFULL
TI Alpha-1a adrenergic receptor antagonists
IN Patane, Michael A., Harleysville, PA, United States
Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Lansdale, PA, United States

Ponticello, Rose Ann, Harleysville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5661163 19970826 <--
AI US 1995-488272 19950607 (8)
DT Utility
FS Granted
LN.CNT 1613
INCL INCLM: 514/331.000
INCLS: 514/330.000; 514/284.000; 546/215.000; 546/225.000
NCL NCLM: 514/331.000
NCLS: 514/284.000; 514/330.000; 546/215.000; 546/225.000
IC [6]
ICM: A61K031-445
ICS: C07D211-36
EXF 514/316; 514/318; 514/326; 514/327; 514/331; 514/330; 514/284; 546/194;
546/205; 546/206; 546/213; 546/214; 546/215; 546/221; 546/225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 63 OF 66 USPATFULL on STN
AN 97:49744 USPATFULL
TI Process for preparing morpholine tachykinin receptor antagonists
IN Dorn, Conrad P., Plainfield, NJ, United States
Hale, Jeffrey J., Westfield, NJ, United States
Finke, Paul E., Milltown, NJ, United States
MacCoss, Malcolm, Freehold, NJ, United States
Mills, Sander G., Woodbridge, NJ, United States
Shah, Shrenik K., Metuchen, NJ, United States
Chambers, Mark S., Watford Harts, England
Harrison, Timothy, Great Dunmow, England
Ladduwahetty, Tamara, Buckhurst Hill, England
Williams, Brian J., Great Dunmow, England
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5637699 19970610 <--
AI US 1995-445489 19950522 (8)
RLI Division of Ser. No. US 1993-169889, filed on 17 Dec 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1993-61914, filed on 19
May 1993, now abandoned which is a continuation-in-part of Ser. No. US
1992-971448, filed on 4 Nov 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1992-905976, filed on 29 Jun 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 6269
INCL INCLM: 540/524.000
INCLS: 544/111.000; 544/114.000; 544/121.000; 544/122.000; 544/124.000;
544/129.000; 544/132.000; 544/133.000; 544/134.000; 544/137.000;
544/139.000; 544/140.000; 544/141.000; 544/143.000; 544/148.000;
544/153.000; 544/174.000
NCL NCLM: 540/524.000
NCLS: 544/111.000; 544/114.000; 544/121.000; 544/122.000; 544/124.000;
544/129.000; 544/132.000; 544/133.000; 544/134.000; 544/137.000;
544/139.000; 544/140.000; 544/141.000; 544/143.000; 544/148.000;
544/153.000; 544/174.000
IC [6]
ICM: C07D413-02
ICS: C07D265-28; C07D265-30; C07D265-34
EXF 544/174; 544/139; 544/153; 544/146; 544/137; 544/143; 544/133; 544/138;
544/114; 544/140; 544/124; 544/122; 544/141; 544/127; 544/132; 544/134;
544/111; 544/148; 544/121; 544/129; 540/524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 64 OF 66 USPATFULL on STN
AN 97:31715 USPATFULL
TI Alpha-1a adrenergic receptor antagonists
IN Patane, Michael A., Harleysville, PA, United States
Bock, Mark G., Hatfield, PA, United States
Friedinger, Roger M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5620993 19970415 <--
AI US 1995-488267 19950607 (8)
DT Utility
FS Granted
LN.CNT 1220
INCL INCLM: 514/321.000
INCLS: 514/284.000; 514/252.000; 514/253.000; 514/318.000; 514/326.000;
514/327.000; 514/328.000; 514/330.000; 514/331.000; 544/224.000;

NCL NCLM: 544/238.000; 544/239.000; 544/240.000; 546/198.000; 546/194.000;
546/193.000; 546/213.000; 546/214.000; 546/215.000; 546/077.000;
NCLS: 546/217.000; 546/219.000; 546/221.000; 546/228.000; 546/234.000
514/321.000
514/252.010; 514/252.030; 514/252.050; 514/252.060; 514/284.000;
514/318.000; 514/326.000; 514/327.000; 514/328.000; 514/330.000;
514/331.000; 544/224.000; 544/238.000; 544/239.000; 544/240.000;
546/077.000; 546/193.000; 546/194.000; 546/198.000; 546/213.000;
546/214.000; 546/215.000; 546/217.000; 546/219.000; 546/221.000;
546/228.000; 546/234.000

IC [6]

ICM: A61K031-445

ICS: C07D211-42

EXF 546/198; 546/194; 546/77; 546/215; 546/217; 546/219; 546/221; 546/228;
546/234; 546/193; 546/213; 546/214; 514/252; 514/253; 514/284; 514/318;
514/321; 514/326; 514/327; 514/328; 514/330; 514/331; 544/238; 544/224;
544/239; 544/240

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 65 OF 66 USPATFULL on STN

AN 96:38897 USPATFULL

TI Naphthyl bradykinin receptor antagonists

IN Bruns, Jr., Robert F., Carmel, IN, United States

Gehlert, Donald R., Indianapolis, IN, United States

Howbert, J. Jeffry, Bellevue, WA, United States

Lunn, William H. W., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)

PI US 5514675 19960507

AI US 1994-327519 19941020 (8)

<--

DT Utility

FS Granted

LN.CNT 1129

INCL INCLM: 514/229.500

INCLS: 514/248.000; 514/280.000; 514/284.000; 514/393.000; 514/400.000;
514/724.000; 568/303.000; 568/305.000; 568/308.000; 568/326.000

NCL NCLM: 514/229.500

NCLS: 514/248.000; 514/280.000; 514/284.000; 514/393.000; 514/400.000;
514/724.000; 568/303.000; 568/305.000; 568/308.000; 568/326.000

IC [6]

ICM: C07C049-203

ICS: C07C049-115; C07C049-00

EXF 514/229.5; 514/248; 514/280; 514/284; 514/393; 514/400; 514/724; ;
568/303; 568/305; 568/308; 568/326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 66 OF 66 USPATFULL on STN

AN 96:36566 USPATFULL

TI Treatment of emesis with morpholine tachykinin receptor antagonists

IN Dorn, Conrad P., Plainfield, NJ, United States

MacCoss, Malcolm, Freehold, NJ, United States

Hale, Jeffrey J., Westfield, NJ, United States

Mills, Sander G., Woodbridge, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5512570 19960430

AI US 1995-450507 19950525 (8)

<--

RLI Division of Ser. No. US 1994-206771, filed on 4 Mar 1994

DT Utility

FS Granted

LN.CNT 6501

INCL INCLM: 514/236.200

INCLS: 514/235.500; 514/235.800; 514/236.500; 514/236.800; 514/237.200

NCL NCLM: 514/236.200

NCLS: 514/235.500; 514/235.800; 514/236.500; 514/236.800; 514/237.200

IC [6]

ICM: A61K031-535

ICS: C07D413-00

EXF 514/235.8; 514/236.5; 514/236.2; 514/236.8; 514/235.5; 514/237.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

STN INTERNATIONAL LOGOFF AT 12:29:03 ON 26 AUG 2004